**HDP: Annual General Mandate 2024**

On April 25, 2024, HaTinh Pharmaceutical Joint Stock Company announced General Mandate No. 01-2024/NQ-DHDCD as follows:

‎‎Article 1. Approve the Report of the Board of Directors on the activities of the Board of Directors in 2023 and the strategic goals for 2024.

‎‎Article 2. Approve the Report of the Executive Board on the results of production and business activities in 2023 and the orientation and tasks for 2024.

‎‎Article 3. Approve financial performance report in 2023 and financial plan for 2024.

‎‎Article 4. Approve the Report on activities of the Supervisory Board in 2023 and plan for 2024.

‎‎Article 5. Approve the proposal on business performance results in 2023 and the production and business plan for 2024.

1. Results of production and business activities in 2023:

Unit: million VND

|  |  |  |  |
| --- | --- | --- | --- |
| No. | Target | 2023 | 2022 |
| 1 | Total asset value | 265,621 | 286,274 |
| 2 | Owners’ equity | 126,273 | 130,746 |
| 3 | Net revenue | 416,217 | 473,581 |
| 4 | Profit from business activities | 15,736 | 21,156 |
| 5 | Other profits | (108) | (9) |
| 6 | Profit before tax | 15,628 | 21,147 |
| 7 | Profit after tax | 12,428 | 16,850 |

Source: Audited Financial Statements for 2023 of the Company

1. The Company's business plan for 2024:

* Total revenue of VND 480 billion, of which manufactured goods account for VND 400 billion.
* Profit after tax in 2024 reaches VND 15 billion - 20 billion, paying dividends to shareholders from 12%/year - 20%/year in cash or shares.
* Implement projects and investments:
* Continue to invest in current machinery, equipment, and technology lines to increase production capacity and build new lines to increase labor productivity and reduce costs.
* Gradually repair and build new facilities: warehouses, offices for domestic and foreign branches when conditions permit.
* Research the purchase of houses and land to build for the Company's foreign branches when conditions permit: Hanoi Branch... and some localities when it is necessary to expand the market.
* Register new topics in 2024 to improve research and development of new products of value to serve consumers. Register to research biosimilar products.
* To continue expanding the distribution network, it is necessary to have a plan to open more branches, representative offices, and one-member limited liability companies of the Company when there is a necessary requirement for the market.
* Complete enterprise management software and digital transformation.
* Expand joint ventures and associations at home and abroad to increase resources and exports.
* Research and innovate the management mechanism, attract and rejuvenate the team of good scientific, technical and management staff to quickly integrate the company with development trends.
* Pay dividends for 2023 in cash at the rate of 12%.

‎‎Article 6. Approve the Proposal on profit distribution plan for 2023, dividend payment for 2023 and profit distribution plan, dividend payment for 2024 of the Company as follows:

1. Distribution of profit in 2023:

|  |  |  |
| --- | --- | --- |
| No. | Content | Amount (VND) |
| 1 | Charter capital | 99,344,180,000 |
| 2 | Net revenue | 416,217,077,847 |
| 3 | Profit before tax | 15,628,407,330 |
| 4 | Payable Corporate income tax | 3,200,326,997 |
| 5 | Profit after tax | 12,428,080,333 |
| 6 | Profit distribution and dividend payment; | 12,421,301,600 |
| a | Appropriation for funds | 500,000,000 |
| - | Appropriation for Investment and development fund | 500,000,000 |
| - | Appropriation for bonus and welfare fund | 0 |
| b | Pay 12% dividend in cash, expected payment amount | 11,921,301,600 |

1. Plan for profit distribution and dividend payment in 2024

|  |  |  |
| --- | --- | --- |
| No. | Content | Plan (million VND) |
| 1 | Total revenue | 480,000 |
| 2 | Profit after tax | 15000- 20000 |
| 3 | Appropriation for funds | 1000- 2000 |
| 4 | Dividend payment in cash or shares | 12%/year - 20%/year |

‎‎Article 7. Approve the proposal on the remuneration report of the Board of Directors and the Supervisory Board in 2023 and the remuneration of the Board of Directors and the Supervisory Board in 2024.

1. Report on the remuneration of the Board of Directors and the Supervisory Board in 2023:

|  |  |  |  |
| --- | --- | --- | --- |
| Remuneration for the Board of Directors and the Supervisory Board: | Number of people (a) | Remuneration/month (b) | Amount (c)=(a)\*(b)\*12 |
| Chair of the Board of Directors | 1 | 15,000,000 | 180,000,000 |
| Member of the Board of Directors | 4 | 12,000,000 | 576,000,000 |
| Chief of the Supervisory Board | 1 | 8,000,000 | 96,000,000 |
| Member of the Supervisory Board | 2 | 6,000,000 | 144,000,000 |
| Total | 8 |  | 996,000,000 |

1. Approve the remuneration for the activities of the Board of Directors and the Supervisory Board in 2024:

|  |  |  |  |
| --- | --- | --- | --- |
| Remuneration for the Board of Directors and the Supervisory Board: | Number of people (a) | Remuneration/month (b) | Amount (c)=(a)\*(b)\*12 |
| Chair of the Board of Directors | 1 | 25,000,000 | 260,000,000 |
| Member of the Board of Directors | 4 | 20,000,000 | 832,000,000 |
| Chief of the Supervisory Board | 1 | 15,000,000 | 152,000,000 |
| Member of the Supervisory Board | 2 | 10,000,000 | 208,000,000 |
| Total | 8 |  | 1,452,000,000 |

Notes:

* From January to April 2024: The remuneration of the Board of Directors and the Supervisory Board is received according to General Mandate No. 01-2023/NQ-DHDCD dated April 26, 2023 of HaTinh Pharmaceutical Joint Stock Company.
* From May to December 2024: The remuneration of the Board of Directors and the Supervisory Board is received according to the new level of the General Meeting of Shareholders in 2024.

‎‎Article 8. Approve the Proposal on selecting the audit company for 2024 for the Company.

The General Meeting unanimously approves the selection of an independent audit company as proposed by the Supervisory Board and assigns the Managing Director to sign a contract to provide auditing services with the selected independent audit company to perform the audit and review of the Company's Financial Statements 2024.

‎‎Article 9. The General Meeting of HaTinh Pharmaceutical Joint Stock Company approves the entire contents of this General Mandate.

The General Meeting of HaTinh Pharmaceutical Joint Stock Company assigns the Board of Directors of the Company to direct the implementation and the Supervisory Board to supervise the implementation of the contents of this General Mandate. The General Mandate takes effect from the date of signing.